HIV Prevention

Resource Center

Podcasts

Disease Prevention

HIV-TB Prevention Therapies and Vaccine Research

06/21/2022

In this podcast, Michael Reid, MD, from University of California, San Francisco, discusses the newest HIV-TB prevention therapies, the latest research on a new tuberculosis vaccine, and more.

06/21/2022

treatment

Brooke Nichols, PhD, on Measuring PrEP Program Effectiveness Using Routine Data

03/17/2022

In this podcast, Brooke Nichols, PhD, answers our questions about her team's novel and pragmatic metric to evaluate and compare pre-exposure prophylaxis program effectiveness using routine implementation...

03/17/2022

HIV Prevention

Daniel R. Kuritzkes, MD, on HIV Resistance After PrEP

10/14/2021

He talks about HIV resistance in the context of pre-exposure prophylaxis use, how common it is, and how PrEP might influence subsequent therapies.

10/14/2021

HIV Prevention

Hyman Scott, MD on an Overview of PrEP Therapy

07/20/2018

Dr Hyman Scott from the UCSF-Glastone Center for AIDS Research discusses pre-exposure prophylaxis (PrEP) therapy, its indications, and clinical data surrounding its use.

07/20/2018

For more infectious diseases content, visit the Resource Center

Pre-exposure prophylaxis (PrEP) is a preventive medication administered intravenously or orally to reduce the risk of human immunodeficiency virus (HIV) infection that may occur following sex or injection drug use.

For more infectious diseases content, visit the Resource Center

Any licensed health care provider can prescribe PrEP. Among clinicians who are most likely to prescribe PrEP are:

primary care providers; internal medicine specialists; infectious disease specialists

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had a partner with HIV

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had sex without consistently using a condom

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- have been diagnosed with a sexually transmitted disease in the past 6 months

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who inject drugs, have an injection partner with HIV, or share needles, syringes, or other drug injection equipment

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who have previously been prescribed PrEP, have reported continued risky behavior, or previously used multiple courses of PrEP

For more infectious diseases content, visit the Resource Center

The HIV Risk Incidence Index for Men Who Have Sex With Men (HIRI-MSM) and Injection Drug Users Risk Index (IDU) are often used to stratify risk in patients.

For more infectious diseases content, visit the Resource Center

PrEP may reduce HIV transmission from sex by 99% when taken as prescribed.

For more infectious diseases content, visit the Resource Center

The use of PrEP among recommended users increased from 3% in 2015 to 25% in 2020.

For more infectious diseases content, visit the Resource Center

Sources:

For more infectious diseases content, visit the Resource Center

HIV Prevention Snapshot

Reviewed by Daniel Erias, MD and Jeffrey Kwong, DNP, MPH, AGPCNP-BC

Research Summaries

research summary

research summary

Directly Observed Therapy Accurately Measures PrEP Adherence

09/26/2023

Leigh Precopio

Pre-exposure prophylaxis (PrEP) adherence continues to be one of the main challenges for the elimination of HIV transmission. Researchers tested the use of an automated directly observed therapy...

09/26/2023

research summary

research summary

Text Message Intervention Supports PrEP Adherence Among Some At-Risk Populations

08/28/2023

Leigh Precopio

In a recent study, researchers examined the effectiveness of text messaging to support the use of pre-exposure prophylaxis use in certain patient populations who are at high-risk of HIV infection.

08/28/2023

research summary

Individuals Seeking Mpox Vaccination Are Also at Increased Risk of STIs, HIV

04/27/2023

Leigh Precopio

Researchers aimed to determine the risk profile of individuals without HIV who were seeking vaccination against mpox and if these patients would benefit from HIV pre-exposure prophylaxis use.

04/27/2023

CONFERENCE CONVERAGE

Urine Test Shows Predictive Values for PrEP Adherence

04/24/2023

Researchers determined the predictive value of urine point-of-care tenofovir antibody test and compared the results against self-reported PrEP use and TFV-diphosphate levels in dried blood spots. Their...

04/24/2023

Conference Coverage

TDF/FTC Considered Safe Among Pregnant Women Per Objective TFV-DP Levels

03/20/2023

Researchers compared pre-exposure prophylaxis (PrEP) use with birth outcomes using objective levels of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) of women during the second or third trimester...

03/20/2023

April 2024

Current Issue

April 2024

Volume 64

Issue 4